We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Key Regulator of Cancer-Inducing Alternative Splicing Identified

By LabMedica International staff writers
Posted on 17 Sep 2014
Print article
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).
Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread.

RBM4 is known to be crucial to gene splicing by minimizing the effects of cancer-inducing alternative splicing. Alternative splicing is a process by which the exons of the RNA produced by transcription of a gene are reconnected in multiple ways during RNA splicing. The resulting different mRNAs may be translated into different protein isoforms, thereby allowing a single gene to code for multiple proteins.

Alternative splicing occurs as a normal phenomenon in eukaryotes, where it greatly increases the biodiversity of proteins that can be encoded by the genome. In humans about 95% of multiexonic genes are alternatively spliced. Numerous modes of alternative splicing have been observed, of which the most common is exon skipping. In this mode, a particular exon may be included in mRNAs under some conditions or in particular tissues, and omitted from the mRNA in others. Abnormal variations in splicing have also been implicated in disease, since a large proportion of human genetic disorders result from splicing variants. Abnormal splicing variants are also thought to contribute to the development of cancer.

RBM4 activity was found to be reduced in patients with certain types of cancer, including lung and breast cancers, while higher levels of activity correlated positively with improved prospects for survival. Investigators at the University of North Carolina (Chapel Hill, USA) sought to clarify how RBM4 prevented alternative splicing.

They reported in the September 8, 2014, issue of the journal Cancer Cell that RBM4 suppressed proliferation and migration of various cancer cells by specifically controlling cancer-related splicing. Particularly, RBM4 regulated Bcl-x splicing to induce apoptosis, and coexpression of Bcl-xL partially reversed RBM4-mediated tumor suppression.

The pro-survival protein BCL-xL is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. BCL-xL (B-cell lymphoma-extra-large) is a transmembrane molecule in the mitochondria. It is a member of the BCL-2 family of proteins, and acts as a pro-survival protein by preventing the release of mitochondrial contents such as cytochrome c, which would lead to caspase activation.

“Historically, scientists have not targeted the proteins in cancer cells that are involved in gene splicing,” said senior author Dr. Zefeng Wang, associate professor of pharmacology at the University of North Carolina. “This is a whole new ballgame in terms of gene regulation in cancer. In normal cells, RBM4 inhibits alternative splicing. It makes genes splice from a long form into a short form. For one of the genes we study, which is called Bcl-x, we want the short form because it has anticancer properties. When RBM4 is low, the longer form of Bcl-x is produced, which plays a role in promoting cancer development and metastasis. In mouse models, we showed that activating RBM4 can reverse cancer progression.”

The investigators also discovered that RBM4 played a role in regulating serine/arginine-rich splicing factor 1 (SRSF1), which is highly active in some cancer cells. “What is interesting is that RBM4 actually inhibits the expression of SRSF1 and therefore controls the splicing of many SRSF1 targets in an opposite fashion. This again showed us why RBM4 has activity as a tumor suppressor,” said Dr. Wang.

The result is that this study firmly established RBM4 as a tumor suppressor with therapeutic and prognostic potential.

Related Links:

University of North Carolina


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.